MLYS vs. PHAR, LYEL, ZYME, SVRA, SLN, CALT, GHRS, AVBP, ORIC, and PHAT
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Pharming Group (PHAR), Lyell Immunopharma (LYEL), Zymeworks (ZYME), Savara (SVRA), Silence Therapeutics (SLN), Calliditas Therapeutics AB (publ) (CALT), GH Research (GHRS), ArriVent BioPharma (AVBP), ORIC Pharmaceuticals (ORIC), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical preparations" industry.
Pharming Group (NASDAQ:PHAR) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.
Pharming Group received 1 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 50.00% of users gave Pharming Group an outperform vote.
Pharming Group has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500.
0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Mineralys Therapeutics has a net margin of 0.00% compared to Mineralys Therapeutics' net margin of -4.01%. Mineralys Therapeutics' return on equity of -4.61% beat Pharming Group's return on equity.
Pharming Group has higher revenue and earnings than Mineralys Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
Pharming Group presently has a consensus target price of $37.00, indicating a potential upside of 297.85%. Mineralys Therapeutics has a consensus target price of $33.50, indicating a potential upside of 157.69%. Given Mineralys Therapeutics' higher possible upside, equities analysts plainly believe Pharming Group is more favorable than Mineralys Therapeutics.
In the previous week, Pharming Group had 5 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 7 mentions for Pharming Group and 2 mentions for Mineralys Therapeutics. Pharming Group's average media sentiment score of 1.14 beat Mineralys Therapeutics' score of 0.92 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.
Summary
Pharming Group and Mineralys Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
